Sarcomatoid differentiation (RCC)
A spindle-cell change found in about 10% of kidney cancers that makes them aggressive and, unexpectedly, unusually responsive to immunotherapy.
Sarcomatoid RCC (any histology) has median survival under a year on TKIs alone, but in CheckMate 214 nivolumab-ipilimumab produced ORR ~60% and complete responses in ~20%, with OS HR ~0.45. High PD-L1 and immune infiltration explain the paradox. Guidelines favour IO-based regimens in sarcomatoid disease.
Pages like this
not linked directly; found by shared links- TermIMDC risk groups (favourable / intermediate / poor)
Shares CheckMate 214, IMDC risk → first-line regimen choice (RCC), Renal cell carcinoma.
- TrialCOSMIC-313
Shares Ipilimumab, Nivolumab, Renal cell carcinoma.
- TrialCheckMate 648
Shares Ipilimumab, Nivolumab.
- TrialCheckMate 9DW
Shares Ipilimumab, Nivolumab.
- PersonJames Larkin
Shares Ipilimumab, Nivolumab, Renal cell carcinoma.
- TrialTiNivo-2
Shares Nivolumab, Renal cell carcinoma.
- ProductAxitinib
Shares IMDC risk → first-line regimen choice (RCC), Renal cell carcinoma.
- TermImmune-related endocrinopathies (thyroiditis, hypophysitis)
Shares Ipilimumab, Nivolumab.